APPLY: APPLYING CLINICAL TOOLS – EARLY PSYCHOSIS ACCREDITED PROGRAM

The APPLY: Applying Clinical Tools – Early Psychosis program, was developed by the Canadian Psychiatric Association with Janssen Inc.

Please click the links below to access the tools.

Program Faculty:

          Dr Phil Tibbo (Program Chair)
          Dr Rebecca Carriere

            Dr Pierre Chue

              Dr Howard Margolese

Program Objectives:

            After participating in this program, focused on the early phase of illness, participants will:

          • Identify the need and opportunity for using clinical tools to prevent relapse and promote positive outcome;
          • Apply the use of clinical tools to the following areas of practice:
            • Antipsychotic Treatment Selection
            • Patient Engagement in Treatment Choice
            • Monitoring Antipsychotic Side Effects

Preventing Relapse in Early-Phase Schizophrenia: Pharmacotherapy Considerations During this Critical Period

Check out a new video featuring CCEIP members Phil Tibbo, Pierre Chue and Howard Margolese.

Learning Objectives;

  • Review the importance of early relapse prevention in schizophrenia
  • Discuss how day-to-day functioning and clinical outcomes may vary for newly diagnosed patients with schizophrenia who are treated with oral vs long-acting injectable (LAI) antipsychotics

Click here to view video

CCEIP: Position Statement on Cannabis Legalization

The federal government has committed to legalizing and regulating access to cannabis in 2017. The recently released recommendations of the Task Force on Marijuana Legalization and Regulation (Task Force) to the Federal government was prepared to inform the design of the new framework. The Task force engaged multi-stakeholder groups and knowledge leaders in the development of their recommendations.

This CCEIP position statement on cannabis is focused on the health of the youth and young adults we serve.

CCEIP: Position Statment on Cannabis Legalization

Maybe it’s not just a bad trip: Bold new Nova Scotia-based cannabis education campaign created with youth, for youth, busts through myths and misconceptions of marijuana use

A thought-provoking education campaign called Weed Myths and launched Monday by the Mental Health Foundation of Nova Scotia and Nova Scotia Early Psychosis Program aims to shed much-needed light on misconceptions surrounding marijuana use.

A recent national study shows that Canadian youth are the top users of cannabis in the developed world, with one in five people between the ages of 15 and 24 years old reporting daily or almost daily use of the substance.

The report, titled What Canadian Youth Think about Cannabis and produced by The Canadian Centre on Substance Abuse, also states that youth between the ages of 14 and 19 years old feel that weed is “much safer than alcohol and tobacco” and is “not as dangerous as drunk driving.”

Perceptions among Canadian youth such as driving while high is harmless are extremely dangerous. Data collected by the National Fatality Database between 2000 and 2010 reveals that cannabis was the most common illicit drug present among fatally injured drivers between the ages of 15 and 24 years old.

That’s why this new attention-grabbing awareness Weed Myths campaign has been developed and funded by both the Mental Health Foundation of Nova Scotia (MHFNS) and Nova Scotia Early Psychosis Program (NSEPP). The campaign features graphic bus shelter posters and print advertisements across Halifax Regional Municipality, along with engaging photos and videos for social media platforms such as Instagram and YouTube.

“We are incredibly proud of our partnership with Dr. Philip Tibbo and the NSEPP,” says Mental Health Foundation of Nova Scotia president and CEO Starr Dobson.  “We know mental illness typically strikes between the ages of 16 and 24, and cannabis can have negative effects, both short- and long term-, on mental wellness when used regularly at this age. This message couldn’t be better targeted or more necessary.”

In fact, Canadian youth helped create the Weed Myths campaign, offering feedback on how the promotional materials look, how to target people in their own age group and how to focus messages so that they have an impact on their audience, ultimately reducing harm-associated with cannabis use.

“Regular cannabis use in the emerging adult is not benign. A public health approach is needed to educate youth so that they themselves can make informed decisions,” says Nova Scotia Early Psychosis Program director Dr. Phil Tibbo.

“This campaign is unique as not only was there a great partnership between the MHFNS, NSEPP and creative team at Kohoot, but its relevance comes from the direct input and direction from the youth themselves,” he says. “We have focused on two of the more common myths of cannabis use in this age group, but there are more.”

Twenty-one per cent of 18- and 19-year-olds reported riding with a driver who had used cannabis in the What Canadian Youth Think about Cannabis study.

“When most citizens think of impaired driving, they automatically think of driving while under the influence of alcohol – but what they may not realize is that impaired driving also means driving while under the influence of any drug, such as cannabis,” says Nova Scotia Chiefs of Police Association (NSPCA) president Chief Peter McIsaac.

“And whether it is drug or alcohol related, impaired driving poses extreme dangers and carries the same criminal penalties, including loss of driver’s licence, a criminal record, fines, jail time and more,” he says. “When a motorist drives impaired, it’s a decision that not only puts their own lives and the lives of others on the road at risk, but one that can have a lasting impact on friends, family and loved ones.”

This important new Weed Myths campaign targets youth between 16 and 20 years old to let them know that driving while high is harmful – not harmless – and emphasize the many other negative mental and physical consequences of cannabis use.

Visit www.weedmyths.ca to learn more, go to the Weed Myths YouTube channel to watch the videos and email info@weedmyths.ca for more information.

New Executive Members announcement

The Canadian Consortium for Early Intervention in Psychosis is pleased to announce the appointment of a new Executive Member team, which was voted in at the Annual General Meeting in Toronto, ON held September 21st, 2016.

Executive Members Dr Philip Tibbo and Dr Marc-André Roy have been voted to President and Vice President respectively. Dr Tibbo is a professor in the Department of Psychiatry at Dalhousie University, the Dr. Paul Janssen Chair in Psychotic Disorders, the Director of the Nova Scotia Early Psychosis Program and the Co-Director of the Nova Scotia Psychosis Research Unit.  Dr Roy is a researcher at the Research Center of the Institut Universitaire en Santé Mentale de Québec, Associate Professor in the department of psychiatry and neuroscience at Laval University, and Head Psychiatrist at the Clinique Notre-Dame des Victoires.

Joining the Executive Team as Directors at Large are:

  • Dr Amal Abdel-Baki, clinical associate professor at the faculty of Medicine at the University of Montréal, and head of research of la Clinique des Jeunes Adultes psychotiques (JAP);
  • Dr Andrea Bardell, clinical assistant professor at the University of British Columbia and clinical lead of the EPI Program at Island Health in Victoria; and
  • Dr Thomas Hastings, associate clinical professor in the department of psychiatry at McMaster University, and lead psychiatrist and director for the Phoenix Program in Oakville.

Thank you to Dr Ashok Malla and Dr Thomas Raedler for their contributions to the CCEIP executive team.

Congratulations to the new Executive Member team, and good luck moving forward.

IEPA Conference 2016

The Canadian Consortium for Early Intervention in Psychosis was proud to be involved in several POSTER presentations at this year’s International Early Psychosis Association (IEPA) Conference, held in Milan, Italy from October 19th to October 22nd.

One poster, New clinical tools for intervention in early phase psychosis was presented by Dr. Phil Tibbo, and showcased clinical tools created by the CCEIP: The Relapse Risk Assessment in Early Phase Psychosis Tool, the Antipsychotic Treatment Selection Tool, and the Tool for Monitoring Antipsychotic Side Effects (TMAS).

Dr. Tibbo also presented a poster Preliminary exploration of the current use of long-acting injectable antipsychotics in Canadian early intervention services for psychosis, which was designed with the aim to assess feasibility of data collection and generate pilot data to inform a larger scale investigations of the use of LAIs in Canadian EIS.

Finally, Dr. Marc-André Roy presented a poster Clozapine Use in Early-Intervention programs across Canada, which showcased the use of Clozapine in early-intervention program nationwide.

iepa-2  iepa-3  IEPA Conference 2016

International Early Psychosis Association (IEPA) Conference in Milan, October 2016

In co-operation with the Nova Scotia Early Psychosis Program (NSEPP), the Canadian Consortium for Early Intervention in Psychosis is involved in several presentations at this year’s International Early Psychosis Association (IEPA) Conference being held in Milan, Italy from October 19th – October 22nd.

The presentations are listed below:

  1. Improving the transition from early intervention services to community careP Tibbo et al (poster)
  2. Clozapine use in Early Intervention Programs Across CanadaMA Roy et al (poster)
  3. Early Intervention for Psychosis in Quebec (Canada): Successes and Challenges for Both Academic and Non-Academic ProgramsM Nolan et al (poster)
  4. Key Findings in Early Psychosis: A Knowledge Sharing InitiativeP Tibbo et al. (poster)
  5. Preliminary exploration of the current use of long-acting injectable antipsychotics in Canadian early intervention services for psychosisP Tibbo et al. (poster)
  6. The CCEIP Decision-Making ToolP Tibbo et al (poster)
  7. The CCEIP Relapse Risk Assessment in Early Phase Psychosis QuestionnaireP Tibbo et al (poster)
  8. Vulnerability to the effects of cannabis on transition to psychosisK Aitchison et al (symposium)

For more information, please click here.

 

SSC Breakout Session: Relapse Risk Assessment and Intervention in Early Psychosis

Conference Details
Schizophrenia Society of Canada – 2016 National Conference
World Trade & Convention Centre
Halifax, Nova Scotia
October 27 & 28, 2016

Breakout Session Details
Friday, October 28th
11:15 am
Room B: Presentations
Early Intervention

Speakers
Phil Tibbo, MD, FRCPC

Overview:
Rates of relapse are alarmingly high in young people diagnosed with a first-episode psychosis. The majority (82%) will experience a relapse of the first-episode within the first five years of illness, of which 78% will experience a second relapse within the same time frame.  Individuals who have recurrent episodes of relapse are at high risk for developing a chronic trajectory of the illness with important functional decline and increased risk for suicide. Reducing risk of relapse remains one of the greatest challenges in the treatment of psychosis during the early phase of the illness.

The Canadian Consortium for Early Intervention in Psychosis has created a relapse risk assessment tool to assist family members with early identification of an impending relapse.  The tool evaluates all known risk factors and generic early warning signs, as well as perspectives of patients and their families on the meanings of relapse and early signs of relapse. This workshop will highlight the methodology used for creating the tool, including the results of family focus groups which covered key interview topics such as the importance of relapse, conceptualization of relapse, recognition of relapse (including early warning signs), factors contributing to relapse, and factors preventing relapse.

Register now! http://ssc2016.ca/

CPA Workshop: New Clinical Tools for Intervention in Early Phase Psychosis

New Clinical Tools for Intervention in Early Phase Psychosis

Details
Workshop – W38
Friday, September 23, 2016
16:30 – 18:00
Pier 3

Learning Objectives
At the end of this session participants will be able to:

  1. Apply clinically relevant solutions to address key clinical challenges in the management of early psychosis
  2. Consider the integration of clinical tools in everyday workflow
  3. Recognize the importance of monitoring for side effects and relapse in an early phase psychosis population

Speakers
Ashok Malla, MD, FRCPC; Phil Tibbo, MD, FRCPC;
Tom Hastings, MD, FRCPC; Nicola Banks, BSc

Abstract
An important objective of the CCEIP is to provide clinically relevant solutions that improve patient care. We have recently created clinical tools that address three gaps in early phase psychosis care: relapse risk assessment, monitoring of antipsychotic side effects, and decision support for selection of antipsychotics. Our CPA workshop this September will discuss the need for and development of these tools, and review the tools themselves in an interactive manner. The aim is to have these point-of-care tools incorporated into everyday work flow, including EMR integration.

Click here to register

The Development of National Guidelines for Comprehensive Care in Early Phase Psychosis

The Canadian Consortium for Early Intervention in Psychosis (CCEIP) is committed to the development of comprehensive guidelines for providing services based on and informed by the best available evidence during the critical years of the course of psychosis beginning with the first episode. These guidelines will be designed to cover all aspects of care and treatment for the individual and their family, including methods to improve pathways to care and to reduce delay in treatment.

See full document below.

[gview file=”http://epicanada.org/wp-content/uploads/2015/12/M118-National-Guidelines_v3.pdf”]